TriMod Therapeutics, a biotech startup, has developed TriMoVac, a platform technology that boosts the immune response to tumors, leading to their elimination without the need for chemotherapy. The company's technology has shown promising results in skin, colon, and lung cancer models, with successful tumor rejection upon re-challenge. TriMod is currently optimizing its platform and aims to start clinical trials in cancer patients within two years.